NASDAQ:RXII - RXi Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.53 +0.01 (+0.66 %)
(As of 08/19/2018 02:07 AM ET)
Previous Close$1.53
Today's Range$1.51 - $1.5483
52-Week Range$1.29 - $7.70
Volume31,770 shs
Average Volume323,329 shs
Market Capitalization$6.96 million
P/E Ratio-0.36
Dividend YieldN/A
Beta1.31
RXi Pharmaceuticals logoRXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; and PCI Biotech. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Receive RXII News and Ratings via Email

Sign-up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RXII
CUSIPN/A
Phone508-767-3861

Debt

Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio1.13

Price-To-Earnings

Trailing P/E Ratio-0.36
Forward P/E Ratio-0.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales670.14
Cash FlowN/A
Price / CashN/A
Book Value$0.77 per share
Price / Book1.99

Profitability

EPS (Most Recent Fiscal Year)($4.20)
Net Income$-12,450,000.00
Net MarginsN/A
Return on Equity-314.25%
Return on Assets-170.94%

Miscellaneous

Employees15
Outstanding Shares4,380,000
Market Cap$6.96 million

RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions

What is RXi Pharmaceuticals' stock symbol?

RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII."

When did RXi Pharmaceuticals' stock split? How did RXi Pharmaceuticals' stock split work?

RXi Pharmaceuticals shares reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of RXi Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Corp (NASDAQ:RXII) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company earned $0.06 million during the quarter, compared to analyst estimates of $0.02 million. View RXi Pharmaceuticals' Earnings History.

When is RXi Pharmaceuticals' next earnings date?

RXi Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for RXi Pharmaceuticals.

What price target have analysts set for RXII?

1 brokers have issued 12-month price objectives for RXi Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate RXi Pharmaceuticals' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 96.1% from the stock's current price. View Analyst Price Targets for RXi Pharmaceuticals.

What is the consensus analysts' recommendation for RXi Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RXi Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RXi Pharmaceuticals.

Who are some of RXi Pharmaceuticals' key competitors?

Who are RXi Pharmaceuticals' key executives?

RXi Pharmaceuticals' management team includes the folowing people:
  • Dr. Geert Cauwenbergh, Pres, CEO, CFO & Director (Age 64)
  • Dr. Gerrit Dispersyn Dr. Med. Sc, Chief Devel. Officer (Age 43)
  • Karen Bulock, VP of Research
  • Ms. Caitlin Kontulis, Director of Fin. & Sec. (Age 32)

Has RXi Pharmaceuticals been receiving favorable news coverage?

Media stories about RXII stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.51 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for RXi Pharmaceuticals.

Who are RXi Pharmaceuticals' major shareholders?

RXi Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (2.78%). Company insiders that own RXi Pharmaceuticals stock include Alexey Eliseev, Geert Cauwenbergh and Gerrit Dispersyn. View Institutional Ownership Trends for RXi Pharmaceuticals.

Which institutional investors are buying RXi Pharmaceuticals stock?

RXII stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought RXi Pharmaceuticals stock in the last two years include Geert Cauwenbergh and Gerrit Dispersyn. View Insider Buying and Selling for RXi Pharmaceuticals.

How do I buy shares of RXi Pharmaceuticals?

Shares of RXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RXi Pharmaceuticals' stock price today?

One share of RXII stock can currently be purchased for approximately $1.53.

How big of a company is RXi Pharmaceuticals?

RXi Pharmaceuticals has a market capitalization of $6.96 million and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. RXi Pharmaceuticals employs 15 workers across the globe.

How can I contact RXi Pharmaceuticals?

RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected]


MarketBeat Community Rating for RXi Pharmaceuticals (NASDAQ RXII)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe RXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.